XWELL and iSpecimen are small-cap medical companies compared on profitability, valuation, analyst ratings, ownership, and risk. XWELL shows higher revenue ($33.9M vs. $9.29M) and better earnings metrics, though both are unprofitable. XWELL has lower price-to-earnings ratio and less volatile stock price (beta 0.83 vs. 1.87). Institutional ownership is higher in iSpecimen (13.6%) than XWELL (8.7%), but insider ownership is slightly higher in XWELL. Overall, XWELL leads in 7 out of 11 factors, suggesting it may be the stronger investment option currently.
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
Elevance Health reported strong Q2 2026 results with earnings per share of $7.45, surpassing analyst estimates of around $6.20. Revenue also exceeded expectations at $49.83 billion, marking consistent quarterly outperformance. The company raised its ...
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
